Hydrafacial launches new Syndeo device

Aesthetic treatment company Hydrafacial has unveiled its new technology, Syndeo.

According to the company, the system has been designed with automation features, and is optimised for customisation. The device includes 12 treatments in one system, including LightStim Elipsa LED therapy, lymphatic drainage, Keravive, Perk and Hydrabody. It also incorporates seamless gesture control for less hand-to-surface contact, automatic serum selection, compact gunkie with integrated light and magnifying glass, as well as wireless upgrades. UK and Ireland country manager, Lauren Gibson, said, “We’re thrilled to be launching the new Hydrafacial Syndeo in the UK. Our next generation device is smart, effortless and personalised, elevating every aspect of the Hydrafacial treatment with the most advanced delivery experience to date.”

SkinCeuticals releases new A.G.E Interrupter serum

The Media

VICE highlights botched cosmetic procedures

VICE has shone a light on the detrimental impact of unlicensed aesthetic treatments in Thailand. The documentary, entitled Unlicensed Doctors Botched My Face, shares the story of patients who have undergone injectable procedures from unlicensed practitioners, leading them to require extensive reconstructive surgery. They share that many people in Thailand are more likely to seek unlicensed aestheticians because their services are cheap and easily accessible, with procedures proving particularly popular among young patients who want to emulate K-Pop idols.

Christina Aguilera partners with Merz Aesthetics

American pop icon Christina Aguilera has partnered with Merz Aesthetics, publicly speaking on using Xeomin (incobotulinumtoxinA) to smooth her glabellar lines. Speaking on the treatment and her partnership with the brand, Aguilera said, “I think we all can rely on a little help. Why not?”

Skincare company SkinCeuticals has launched corrective cream A.G.E Interrupter Advanced. According to the company, the product builds on the original A.G.E Interrupter, which was launched 14 years ago, to target visible signs of ageing with more advanced skin technology. The product’s formulation uses wild fruit flavonoids, glycyrrhetinic acid and concentrated proxylane (20% more than the original A.G.E Interrupter) to optimise collagen matrix integrity, according to SkinCeuticals. Dr Ana Mansouri, key opinion leader for SkinCeuticals, commented, “Having reviewed the updated formulation of A.G.E Interrupter Advanced, I will be recommending my patients to implement this into their maintenance regimens post-procedure alongside in-clinic collagen induction procedures such as microneedling. It provides an innovative underlying science of targeting collagen degradation on a multi-dimensional level.”

NHS considering new vitiligo cream

Skin cream ruxolitinib, which can be used by vitiligo patients to restore pigment to the skin, might soon be offered in the UK on the NHS.

From April 2023, the National Institute for Health and Care Excellence (NICE) will commence the process of appraising the product (which carries the brand name Opzelura and has received US Food and Drug Administration approval), awaiting a decision on whether it will receive approval to be prescribed by UK medical practitioners.

The substance can be used to restore the natural pigment of a person’s skin, especially on the white skin patches experienced by vitiligo patients, but it also carries potentially serious side effects like increased susceptibility to infections. Nonetheless, an internal Opzelura study showed significant reduction in pigmentation after using the product for 24 weeks. The European Medicines Agency is also considering approving the medication for use on patients over 12. It is as yet unknown when Opzelura would become publicly available if it is approved.